Skip to main content
. 2019 May 7;11(5):634. doi: 10.3390/cancers11050634

Figure 2.

Figure 2

Schematic representation of putative targets to reprogram the enhancer landscape in cancer. (A) modulators of transcription factors, (B) HAT inhibitors, (C) HDAC inhibitors, (D) BET inhibitors, (E) CDK7/9 inhibitors. HAT: Histone acetyltransferase; HDAC: Histone deacetylase; BET: Bromodomain and extraterminal; CDK: Cyclin-dependent kinases.